NCT00718380 - A Phase 1 Study of ABT-869 in Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions

Solid Tumor

Interventions

DRUG

ABT-869

2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.